Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03948178 · ClinicalTrials.gov registry record · Phase 3
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
A Phase 3 study, sponsored by Orion Corporation, Orion Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 227
- Enrollment target
NCT03948178 is a Phase 3 study that was terminated before completion, run by Orion Corporation, Orion Pharma. The registered enrollment target is 227 participants.
The verdict
NCT03948178, a Phase 3 study, was terminated before completion, sponsored by Orion Corporation, Orion Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 227 participants
- Enrollment target
Study Summary
This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan. The study will also provide more information about long-term safety and effectiveness of oral levosimendan in patients with ALS. This is an open-label study, so that all eligible subjects that complete the double-blind REFALS study (48-weeks of treatment) will have the opportunity to receive oral levosimendan treatment. The primary objective, in addition to continuing treatment for subjects enrolled in the REFALS study, is to evaluate long-term safety of oral levosimendan in ALS patients. Another important objective is to explore long-term effectiveness of oral levosimendan in the treatment of patients with ALS. This study is open only to patients taking part in the REFALS study.
Interventions
- DRUG Levosimendan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2019-06-26 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03948178
The ClinicalTrials.gov registry entry for NCT03948178 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orion Corporation, Orion Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levosimendan is the first listed.
NCT03948178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03948178 about?
NCT03948178 is a clinical study titled "Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension". This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan. The study will also provide more information about long-term safety and effectiveness of oral levosimendan in patients with ALS. This is an open-label study, so t...
What is the current status of trial NCT03948178?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 227 participants. The study started on 2019-06-26. Estimated completion is 2020-11-18.
What interventions are being tested in trial NCT03948178?
The interventions under investigation include: Levosimendan (DRUG).
Who is sponsoring clinical trial NCT03948178?
This trial is sponsored by Orion Corporation, Orion Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.